Pialoux G, Raffi F, Brun-Vézinet F.
et al. A randomized trial of three maintenance regimens given after three
months of induction therapy with zidovudine, lamivudine, and indinavir in
previously untreated HIV-1-infected patients. N Engl J Med.1998;339: 1269-1276.
Havlir DV, Marschner IC, Hirsch MS.
et al. Maintenance antiretroviral therapies in HIV infected patients with
undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med.1998;339:1261-1268.
Reijers MH, Weverling GJ, Jurriaans S.
et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected
Clumeck N, Mundere J, Kabeya K.
et al. MIRO: a randomized trial of maintenance therapy with or without protease
inhibitors after 4 months of triple or quadruple induction therapy. Presented at: the 6th Conference on Retroviruses and Opportunistic
Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 627.
Stuyver L, Wyseur A, Rombout A.
et al. Line probe assay for rapid detection of drug-selected mutations in
the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother.1997;41:284-291.
Nijhuis M, Boucher CA, Schuurman R. Sensitive procedure for the amplification of HIV-1 RNA using a combined
reverse-transcription and amplification reaction. Biotechniques.1995;19:178-180; 182.
Nijhuis M, Boucher CA, Schipper P, Leitner T, Schuurman R, Albert J. Stochastic processes strongly influence HIV-1 evolution during suboptimal
protease-inhibitor therapy. Proc Natl Acad Sci U S A.1998;95:14441-14446.
Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC
combination therapy. Science.1995;269:696-699.
Soussan P, Collin G, Descamps D, Foiny P, Brun-Vézinet F. Detection of M184V 3TC mutation in the HIV1 RT gene by Restriction
Fragment Digestion Assay (RFDA). Presented at: the 4th Conference on Retroviruses and Opportunistic
Infections; Washington, DC; January 22-26, 1997. Abstract 634.
Woolf E, Au T, Haddix H, Matuszewski B. Determination of L-735 524, an human immunodeficiency virus protease
inhibitor, human plasma and urine via high performance liquid chromatography
with column switching. J Chromatogr A.1995;692:45-52.
Hoetelmans RM, Reijers MH, Weverling GJ.
et al. The effect of plasma drug concentrations on HIV-1 clearance rate during
quadruple drug therapy. AIDS.1998;12:F111-F115.
Hochberg Y, Tamhane AC. A sharper Bonferroni procedure for multiple significance testing. Biometrika.1988;75:800-803.
Hirsch MS, Conway B, D'Aquila RT.
et al. Antiretroviral drug resistance testing in adults with HIV infection. JAMA.1998;279:1984-1991.
Condra JH, Holder DJ, Schleif WA.
et al. Genetic correlates of in vivo viral resistance to indinavir, a human
immunodeficiency virus type 1 protease inhibitor. J Virol.1996;70:8270-8276.
Brun-Vézinet F, Calvez V, Descamps D.
et al. M184V mutation is not predictive of therapeutic failure to d4T/3TC
combination. Presented at: the 12th International Conference on AIDS; June 28-July
3, 1998; Geneva, Switzerland. Abstract 32310.
Paes AH, Bakker A, Soe-Agnie CJ. Measurement of patient compliance. Pharm World Sci.1998;20:73-77.
Eron JJ, Benoit SL, Jemsek J.
et al. Treatment with lamivudine, zidovudine, or both in HIV-1 positive patients
with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med.1995;333:1662-1669.
Drusano GL, Bilello JA, Stein DS.
et al. Factors influencing the emergence of resistance to indinavir: role
of virologic, immunologic, and pharmacologic variables. J Infect Dis.1998;178:360-367.
De Pasquale MP, Murphy R, Kuritzkes D.
et al. Resistance during early virological rebound on amprenavir plus zidovudine
plus lamivudine triple therapy or amprenavir monotherapy in ACTG protocol
347. Presented at: 2nd International Workshop on HIV Drug Resistance and
Treatment Strategies; June 24-27, 1998; Lake Maggiore, Italy. Abstract 71.
Calvez V, Mouroux M, Yvon-Groussin A.
et al. Early virologic failures in HIV-infected naïve patients receiving
saquinavir-SGC in combination with d4T/ddC (MIKADO trial, Roche M611002):
genotypic, phenotypic resistance analysis and drug measurement study. Presented at: International Conference on the Discovery and Clinical
Development of Antiretroviral Therapy; December 13-17, 1998; St Thomas, West
Indies. Abstract 19.
Young B, Johnson S, Bahktiari M.
et al. Resistance mutations in protease and reverse transcriptase genes of
human immunodeficiency virus type 1 isolates from patients with combination
antiretroviral therapy failure. J Infect Dis.1998;178:1497-1501.
Mayers DL, Gallahan DL, Martin GL.
et al. Drug resistance genotypes from plasma virus of HIV-infected patients
failing combination drug therapy [abstract]. Antiviral Ther.1997;2(suppl 5):72.
Johnson VA, Nail CD, Hazelwood JD.
et al. Multidrug-resistant HIV-1 isolates from patients with rising plasma
viral burden during double or triple combination therapy in clinical practice
[abstract]. Antiviral Ther.1997;2(suppl 5):72.
Havlir DV, Petropoulos CJ, Hellmann N, Whitcomb JM, Richman DD.and the ACTG 343 team. Evolution of drug resistance associated with loss of viral suppression
in patients treated with indinavir, lamivudine and zidovudine. Presented at: 2nd International Workshop on HIV Drug Resistance and
Treatment Strategies; June 24-27, 1998; Lake Maggiore, Italy. Abstract 74.